Kopfbereich

Schnellnavigation

Hauptnavigation

Dr. Markus Rimann

Dr. Markus Rimann

Dr. Markus Rimann
ZHAW Life Sciences und Facility Management
Einsiedlerstrasse 31
8820 Wädenswil

+41 (0) 58 934 55 12
markus.rimann@zhaw.ch

Persönliches Profil

Tätigkeit an der ZHAW als

Group Leader 3D Tissues and Biofabrication
3D Bioprinting
Development of novel biomaterials
Tissue Engineering
Automated Systems
Competence Centre TEDD (Tissue Engineering for Drug Devlopment and Substance Testing)

www.zhaw.ch/icbt/3d-tissues-and-biofabrication/

Arbeits- und Forschungsschwerpunkte, Spezialkenntnisse

Bioprinting
Development of printable biomaterials (bioinks)
3D cell culture models for drug development and substance testing

Aus- und Fortbildung

Markus Rimann completed his degree in Biology, specialty in Biotechnology, at the ETH Zurich in 2005. As a PhD student he was developing a somatic gene therapy approach to improve cutaneous wound healing. He received his Dr. sc. nat. from the ETH Zurich in 2009. As postdoc at the Center for Applied Biotechnology and Molecular Medicine (CABMM) at the University of Zurich he was focusing on the usage and tracking of mesenchymal stem cells (MSCs) for the treatment of osteoporosis. Since 2011, he works at the Zurich University of Applied Sciences (ZHAW) in the Tissue Engineering team of Prof. Dr. Graf-Hausner. He was involved in initiating the TEDD (Tissue Engineering for Drug Development and Substance Testing) Competence Centre. The TEDD network is a collaborative innovation platform, dedicated to 3D cell culture te¬chnology and organ-like tissue models for drug development, substance testing, personalized and re-generative medicine. The network pools and transfers knowledge and technologies by combining diverse skills through integrative cooperation among academic, clinical and industrial partners. He works with different 3D cell culture systems with or without scaffolds. His research is mainly application-driven to make organotypic model systems available for industry as well as for the clinics. The main focus is on developing 3D cell models for substance testing including automated production, maintenance and analysis. In an approach for personalized medicine osteosarcoma microtissues from patient-derived material were produced and subjected to drug treatment to determine in the future best cancer treatment options. With a scaffold-based cell culture system the entire process of cell encapsulation, maintenance, drug application and viability measurements was automated on a liquid-handling robot to demonstrate HTS-compatibility. As a group leader, he is interested in the further development of the promising bioprinting technology. In different industry projects several tissue models were printed: i) full-thickness skin model for the cosmetic industry to assess harmlessness of cosmetic ingredients, ii) muscle/tendon tissues in a novel 24 well plate for the pharma industry to find new therapeutic treatments for muscle-related diseases, and a kidney model (proximal tubulus of the nephron) to assess nephrotoxicity of drugs. In order to provide suitable bioinks the group is developing printable and cell compatible materials (hydrogels).

Mitglied in Netzwerken

Publikationen